Abstracts tagged "Myositis"

Abstract Number: 0710 • ACR Convergence 2021
Patients with Recent Onset, Active Polymyositis (PM), Dermatomyositis (DM) and Antisynthetase Syndrome (ASS) Have Reduced Muscle Endurance but Not Reduced Muscle Strength Compared to Patients with Established, Low-active Disease
Kristofer Andreasson¹ and Helene Alexanderson², ¹Karolinska Institute, Stockholm, Sweden, ²Karolinska Institutet, Stockholm, Sweden
Background/Purpose: To analyze for differences in quadriceps maximal isometric voluntary contraction (MVIC), muscle endurance (ME), muscle mass and fat mass (m. vastus lateralis, mid-thigh) in…
Abstract Number: 1025 • ACR Convergence 2021
Survival of Patients with Idiopathic Inflammatory Myopathy in Slovenia
Alojzija Hocevar¹, Andrej Virscek², Monika Krosel¹, Matija Tomšič³ and Ziga Rotar³, ¹UKC Ljubjana, Ljubjana, Slovenia, ²Statistical Office of the Republic of Slovenia, Ljubljana, Slovenia, ³Department of Rheumatology, University Medical Centre Ljubljana, Ljubljana, Slovenia
Background/Purpose: Idiopathic inflammatory myopathies (IIM) are a group of rare systemic diseases associated with significant morbidity and mortality. The aim of our study was to…
Abstract Number: 0686 • ACR Convergence 2021
Is It Useful to Assess Muscle Involvement with Positron Emission Tomography in Patients with Idiopathic Inflammatory Myositis? A Case-Control Study
Murat Bektaş¹, Emine Göknur Işık², Fatih Kemik³, Emin Oğuz⁴, Anna ABBASGHOLI ZADEH⁵, Burak Ince⁶, Zeynep Gözde Özkan⁷, Yasemin Yalcinkaya⁸, Bahar Esen⁸, Ahmet Gül⁹ and Murat İnanç⁴, ¹Istanbul Faculty of Medicine, Istanbul, Turkey, ²Istanbul University, Istanbul Faculty of Medicine, Department of Nuclear Medicine, İstanbul, Turkey, ³Istanbul Faculty of Medicine, Istanbul University, Department of Internal Medicine, İstanbul, Turkey, ⁴Istanbul University, Istanbul Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, İstanbul, Turkey, ⁵Istanbul University, Istanbul Faculty of Medicine, Department of Internal Medicine, İstanbul, Turkey, ⁶Istanbul Faculty of Medicine, Istanbul University, Division of Rheumatology, İstanbul, Turkey, ⁷Istanbul Faculty of Medicine, Department of Nuclear Medicine, Istanbul, Turkey, ⁸Division of Rheumatology, Department of Internal Medicine, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey, ⁹Division of Rheumatology, Istanbul University Istanbul School of Medicine, Istanbul, Turkey
Background/Purpose: Multiple diagnostic methods have been used to investigate muscle involvement in patients with idiopathic inflammatory myositis (IIM) such as electromyography (EMG) and muscle MRI.…
Abstract Number: 0711 • ACR Convergence 2021
Suppression of HDL-associated Apolipoprotein A-I (apoA-I) Levels in Patients with Idiopathic Inflammatory Myopathies
Sangmee Bae¹, Ani Shahbazian², Jennifer Wang² and Christina Charles-Schoeman², ¹University of California Los Angeles, Los Angeles, CA, ²Department of Medicine, University of California, Los Angeles, Los Angeles, CA
Background/Purpose: Patients with idiopathic inflammatory myopathies have accelerated vascular disease, which contributes to higher disease morbidity and mortality. Apolipoprotein A-I (apoA-I) is the major protein…
Abstract Number: 1090 • ACR Convergence 2021
Contribution of Scleroderma/Myositis-Related Antibodies Detected by Immunoblot to the Diagnosis of Systemic Autoimmune Rheumatic Diseases in 134 Patients from a Single Referral Center
Diana Prieto-Peña¹, Belén Atienza-Mateo², Miguel Ángel gonzalez-Gay³, Ricardo Blanco⁴ and Marcos Lopez-Hoyos⁵, ¹Hospital Universitario Marqués de Valdecilla, santander, Spain, ²Group "Research in genetic epidemiology and atherosclerosis of systemic diseases and in bone metabolic diseases of the locomotor system", IDIVAL; and Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ³Research group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL, Division of Rheumatology, Hospital Universitario Marqués de Valdecilla; School of Medicine, Universidad de Cantabria, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa, ⁴Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ⁵Marques de Valdecilla University Hospital-IDIVAL, Santander, Spain
Background/Purpose: Immunoblot assays are increasingly used in clinical practice as part of the diagnostic armamentarium of systemic autoimmune rheumatic diseases (SARDs). Our aim was to…
Abstract Number: 0688 • ACR Convergence 2021
Standardized Prevalence Ratios of Cancer in Idiopathic Inflammatory Myositis
Christopher Mecoli¹, Takeru Igusa², Mengkun Chen³, XingYao Wang², Jemima Albayda², Julie Paik², Eleni Tiniakou², Brittany Adler², Carrie Richardson⁴, William Kelly², Sonye Danoff⁵, Andrew Mammen⁶, Elizabeth Platz³, Antony Rosen², Lisa Christopher-Stine², Livia Casciola-Rosen⁷ and Ami Shah⁸, ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Johns Hopkins University, Baltimore, MD, ³Johns Hopkins School of Public Health, Baltimore, MD, ⁴Rush University Medical Center, Chicago, IL, ⁵Johns Hopkins Medicine, Baltimore, MD, ⁶National Institutes of Health, Bethesda, MD, ⁷Johns Hopkins, Baltimore, MD, ⁸Johns Hopkins Rheumatology, Baltimore, MD
Background/Purpose: Whether the likelihood of a cancer diagnosis in idiopathic inflammatory myopathy (IIM) patients differs by autoantibody type is not fully characterized. To inform cancer…
Abstract Number: 0712 • ACR Convergence 2021
Immune Checkpoint Inhibitor-related Myotoxicity : Musculoskeletal and/or Neuromuscular Junction Disorder ?
Hortense Chassepot¹, Lotta Plomp², Dimitri Psimaras³, Thierry Maisonobe³, Sarah Leonard Louis⁴, Isabelle Plu⁴, Mehdi Touat³, Celine Anquetil⁵, Nadege Wesner⁵, Nicolas Champtiaux⁵, Aude Rigolet⁵, Sophie Demeret³, Nicolas Weiss³, Baptiste Abbar⁶, Marie-Claire Bretagne⁷, Bruno Pinna⁷, Capucine Morelot⁸, Martin Dres⁸, Thomas Similowski⁸, Stephane Ederhy⁹, Joe-Elie Salem⁷, Olivier Benveniste⁵ and Yves Allenbach⁵, ¹Universite de Picardie Jules Verne UPJV - Amiens Picardie Hospital, Department of Clinical Immunology and Internal Medicine, Fourqueux, France, ²Amsterdam University Medical Center (AUMC), Amsterdam, Netherlands, ³Sorbonne University - AP-HP, Pitié-Salpêtrière Hospital, Department of Neurology, Paris, France, ⁴Sorbonne University - AP-HP, Pitié-Salpêtrière Hospital, Department of Neuropathology, Paris, France, ⁵Sorbonne University - AP-HP, Pitié-Salpêtrière Hospital, Department of Clinical Immunology and Internal Medicine, Paris, France, ⁶Sorbonne University - AP-HP, Pitié-Salpêtrière Hospital, Department of Oncology, Paris, France, ⁷Sorbonne University - AP-HP, Pitié-Salpêtrière Hospital, Department of Pharmacology, Paris, France, ⁸Sorbonne University - AP-HP, Pitié-Salpêtrière Hospital, Department of Pneumology - R3S, Paris, France, ⁹Sorbonne University - AP-HP, Pitié-Salpêtrière Hospital, Department of Cardiology, Paris, France
Background/Purpose: Immune checkpoint inhibitor (ICI)-related adverse events (irAE) recently emerged as new diseases in the field of auto-immunity. Among them, ICI-related myotoxicity has the highest…
Abstract Number: 1164 • ACR Convergence 2021
A Survey of Treatment Satisfaction with Intravenous Immunoglobulin Among Patients with Inflammatory Myositis
Alan Zhou, Nancy Maltez and Catherine Ivory, University of Ottawa, Ottawa, ON, Canada
Background/Purpose: Intravenous Immunoglobulin (IVIg) is used to treat rheumatic conditions such as Inflammatory Myositis. Subcutaneous Immunoglobulin (SCIg) is an alternative route of administering Immunoglobulin. Studies…
Abstract Number: 0690 • ACR Convergence 2021
Impact of Achieving 2016 ACR/EULAR Response Criteria on Patient Centered Outcome Measures in Myositis
Didem Saygin¹, Siamak Moghadam-Kia², Chester Oddis², Dana Ascherman², Nicole Neiman², Diane Koontz² and Rohit Aggarwal², ¹University of Chicago, Chicago, IL, ²University of Pittsburgh, Pittsburgh, PA
Background/Purpose: The 2016 ACR/EULAR Myositis Response Criteria represent a composite measure that is increasingly being used as a primary end point in myositis clinical trials.…
Abstract Number: 0714 • ACR Convergence 2021
Diagnostic Accuracy of Electromyogram for Myositis
Lois bolko¹, Sarah Leonard Louis², Jean hugues Salmon¹, Olivier Benveniste³, Yves Allenbach³ and Thierry Maisonobe⁴, ¹Rheumatology, CHU maison blanche, Reims, Reims, France, ²Sorbonne University - AP-HP, Pitié-Salpêtrière Hospital, Department of Neuropathology, Paris, France, ³Sorbonne University - AP-HP, Pitié-Salpêtrière Hospital, Department of Clinical Immunology and Internal Medicine, Paris, France, ⁴Sorbonne University - AP-HP, Pitié-Salpêtrière Hospital, Department of Neurology, Paris, France
Background/Purpose: The skeletal muscle biopsy is the gold standard for idiopathic inflammatory myopathies (IIM) diagnosis. Myositis specific antibodies are diagnostic biomarkers for IIM but are…
Abstract Number: 1368 • ACR Convergence 2021
Characterising Exercise Capacity in Systemic Sclerosis Using Cardiac Magnetic Resonance Imaging, Skeletal Muscle Imaging and Cardiopulmonary Exercise Testing
Laura Ross¹, Benedict Costello², Dylan Hansen³, Anniina Lindqvist², Zoe Brown⁴, Andrew Burns⁴, David Prior⁴, Wendy Stevens⁴, Marcus Pianta⁴, Warren Perera⁴, Andre La Gerche² and Mandana Nikpour¹, ¹University of Melbourne at St Vincent's Hospital, Melbourne, Australia, ²Baker Heart and Diabetes Institute, Melbourne, Australia, ³St. Vincent’s Hospital Melbourne, Victoria, Australia, Adelaide, Australia, ⁴St Vincent's Hospital, Melbourne, Australia
Background/Purpose: Impaired exercise capacity contributes to functional impairment, negatively impacting individuals’ quality of life. Functional impairment is notable from early in the disease course of…
Abstract Number: 0691 • ACR Convergence 2021
Serum Cytokine Profiles of Patients with Adult Idiopathic Inflammatory Myopathy
Didem Saygin¹, Partha Biswas², Seyed Mehdi Nouraie², Siamak Moghadam-Kia², Mandy McGeachy², Chester Oddis², Sedin Dzanko², Diane Koontz², Dana Ascherman² and Rohit Aggarwal², ¹University of Chicago, Chicago, IL, ²University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Idiopathic inflammatory myopathies are a heterogenous group of systemic autoimmune diseases characterized by muscle weakness. Serum cytokines and chemokines could shed light on disease…
Abstract Number: 0715 • ACR Convergence 2021
High-Dimensional Analysis Reveals Abnormal B Cell Subsets Associated with Specific Changes to Circulating T and Myeloid Cell Populations in Patients with Idiopathic Inflammatory Myopathies
Erin Wilfong¹, Todd Bartkowiak², Katherine Vowell¹, Camille Westlake¹, Jonathan Irish², Peggy Kendall³, Leslie Crofford¹ and Rachel Bonami¹, ¹Vanderbilt University Medical Center, Nashville, TN, ²Vanderbilt University, Nashville, TN, ³Washington University in St. Louis, St. Louis, MO
Background/Purpose: The idiopathic inflammatory myopathies (IIM) are a clinically heterogeneous group of conditions affecting the skin, muscle, joint, and lung in various combinations. This study…
Abstract Number: 1389 • ACR Convergence 2021
Subclinical ILD Is Frequent and Progresses Across Different Connective Tissue Diseases
Anna-Maria Hoffmann-Vold¹, Helena Andersson², Silje Reiseter², Håvard Fretheim², Imon Barua¹, Torhild Garen³, Øyvind Midtvedt¹, Ragnar Gunnarsson², Michael Durheim², Trond Mogens AAløkken² and Øyvind Molberg¹, ¹Department of Rheumatology, Oslo University Hospital, Oslo, Norway, ²Oslo University Hospital, Oslo, Norway, ³Department of Rheumatology, Oslo University Hospital, Oslo, Nepal
Background/Purpose: Based on the argument that symptoms-define-disease, physicians commonly apply the terms pre-clinical or sub-clinical disease to describe patients with disease-related findings, but no accompanying…
Abstract Number: 0693 • ACR Convergence 2021
Discovery of Antigen Specific CD4+ T Cells in Anti-HMGCR-positive Immune Mediated Necrotizing Myopathy
Eleni Tiniakou¹, Andrew Mammen² and Erika Darrah¹, ¹Johns Hopkins University, Baltimore, MD, ²National Institutes of Health, Bethesda, MD
Background/Purpose: Anti-3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR)-positive immune mediated necrotizing myopathy (anti-HMGCR+ IMNM) is a unique myopathy characterized by IgG autoantibodies against HMGCR and a strong…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.